Recent results of concurrent chemoradiotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma / 肿瘤研究与临床

ABSTRACT

ObjectiveTo investigate the recent treatment result and the toxic responses of chemoradiotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma. MethodsFrom April 2010 to May 2011, 26 initial treatment patients withadvanced esophageal carcinoma were enrolled. The chemotherapy consisted of paclitaxel (135 mg/m2) on day 1 and lobaplatin (35 mg/m2) on day 2,and one cycle continued 21 days. Radiotherapy started on the second day after the fist cycle of chemotherapy. The median total dose was 60 Gy (2 Gy/Fraction,30 fractions,completed in 6 weeks).ResultsThere were 52 cycles in all and mean 2 cycles per patient.CR occurred in 7 patients (26.9 ％),PR in 17 patients (65.4 ％) and SD in 2 patients (7.7 ％).The total effective rate was 92.3 ％ (CR+PR).The toxic responses mainly represented as following,myelotoxicity principally showed leucopenia at grade Ⅰ - Ⅱ occurred 46.1％ (12/26) and at grade Ⅲ-Ⅳ 46.1％ (12/26),thrombopenia at grade Ⅰ - Ⅱ occurred 30.8 ％ (8/26) and at grade Ⅲ-Ⅳ 7.7 ％ (2/26),hypohemoglobinemia at grade Ⅰ - Ⅱ occurred 42.3 ％ (11/26) and at grade Ⅲ 15.4 ％ (4/26).Baldness occurred 84.6 ％(22/26). Pain of muscles or arthralgia occurred 69.2 ％(18/26). Responses of gastrointestinal tract at grade Ⅰ - Ⅱ occurred 11.5 ％ (3/26).Radiation induced esophagitis occurred 88.5 ％ (23/26) and tracheitis 19.2 ％ (5/26).ConclusionThe toxic responses of concurrent chemoradiaotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma are tolerant, and the recent treatment result is good.Further study is needed.